• Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World
Newsy Today
news of today
Home - STAT+
Tag:

STAT+

Health

Acting Head of NIH Infectious Disease Institute Steps Down

by Chief Editor May 21, 2026
written by Chief Editor

Leadership Vacuum at the NIH: What Stability Means for Global Health Security

The revolving door at the National Institutes of Health (NIH) has turned once again. With the recent departure of Jeffery Taubenberger, the acting head of the National Institute of Allergy and Infectious Diseases (NIAID), the scientific community is left grappling with questions about organizational continuity during a period of heightened global health scrutiny.

When leadership roles at critical agencies like the NIAID remain vacant or in constant flux, the impact ripples far beyond Washington, D.C. It affects research prioritization, grant funding cycles, and, the nation’s ability to respond to emerging infectious threats.

The Cost of Leadership Instability

Scientific research is a marathon, not a sprint. It requires long-term vision, consistent funding, and stable leadership to navigate complex regulatory landscapes. When an acting director steps down without a clear succession plan or transparent communication, it creates a vacuum that can stall critical initiatives.

For researchers and stakeholders in the life sciences industry, this lack of transparency is particularly concerning. Effective infectious disease preparedness requires a steady hand to manage the delicate balance between basic research and rapid-response clinical trials. When the “captain” of the ship is constantly changing, the entire research ecosystem risks losing its strategic direction.

Pro Tip: To track real-time changes in federal research leadership, industry professionals should monitor the official NIH news portal and Senate Appropriations Committee hearing transcripts, which often serve as the first point of public disclosure for agency shifts.

Navigating the Future of Infectious Disease Research

The challenges facing the NIAID are not unique. As the global landscape of infectious disease evolves—marked by the rise of antimicrobial resistance and the constant threat of zoonotic spillover—the need for robust, permanent leadership has never been greater.

Navigating the Future of Infectious Disease Research
Jeffery Taubenberger NIAID

Looking ahead, we can expect to see several key trends in how federal health agencies manage these transitions:

  • Increased Scrutiny: Legislators are placing greater emphasis on the stability of key health institutions, likely leading to more frequent oversight hearings.
  • Operational Transparency: There is a growing demand from the scientific community for clearer communication protocols regarding leadership changes.
  • Public-Private Collaboration: As federal leadership faces instability, private research institutions and non-profits may need to take a more active role in maintaining the momentum of long-term studies.

Did You Know?

The NIAID is responsible for conducting and supporting research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. It plays a pivotal role in global health, often serving as the primary funder for vaccine research and development worldwide.

Frequently Asked Questions

Why is a stable leader important for the NIAID?

Stable leadership ensures consistent policy, long-term research strategies, and reliable communication with Congress, which oversees the agency’s substantial annual budget.

Director's Desk: Fighting Infectious Diseases | Dr. Jeffery Taubenberger & NIAID

How do leadership changes affect grant funding?

While funding is often allocated by Congress, internal priorities can shift during leadership transitions. This can sometimes lead to delays in the review and approval processes for new research grants.

Where can I find updates on NIH leadership appointments?

The most reliable sources are the official NIH website and reports from established, specialized news outlets that cover life sciences and healthcare policy.


What are your thoughts on how leadership turnover impacts the pace of medical innovation? Share your perspective in the comments section below, or subscribe to our newsletter for weekly updates on health policy and research trends.

May 21, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

FDA rejects proposal to deregulate AI devices

by Chief Editor April 10, 2026
written by Chief Editor

Health Tech Correspondent

Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth and digital therapeutics. His stories explore how tech is changing the practice of health care and the business and policy challenges to realizing tech’s promise. He’s also the co-author of the free, twice weekly STAT Health Tech newsletter. You can reach Mario on Signal at mariojoze.13.

The Expanding Role of AI in Diagnostics

Artificial intelligence is rapidly moving beyond simple automation in healthcare and becoming a core component of diagnostics. We’re seeing AI algorithms now capable of detecting subtle patterns in medical images – X-rays, MRIs, CT scans – that might be missed by the human eye. PathAI, for example, is using AI to assist pathologists in cancer diagnosis, improving accuracy and reducing turnaround times. This isn’t about replacing doctors, but augmenting their abilities.

The trend isn’t limited to imaging. AI is also being deployed to analyze genomic data, predict patient risk scores, and even diagnose conditions based on voice patterns. A recent study published in Nature Medicine showed an AI model accurately diagnosing depression from speech with 89% accuracy. Expect to see more of these ‘digital biomarkers’ emerge.

The Rise of Personalized Digital Therapeutics

Digital therapeutics – software-based interventions used to treat medical conditions – are gaining traction. But the future isn’t just about generic apps. We’re moving towards highly personalized digital therapeutics powered by AI. These programs will adapt to an individual’s needs, preferences, and responses in real-time, maximizing effectiveness.

Pear Therapeutics, a pioneer in the field, has already received FDA clearance for several digital therapeutics. However, the next generation will be far more sophisticated, incorporating continuous monitoring via wearables and integrating with electronic health records for a holistic view of the patient. This level of personalization requires significant computational power and advanced AI algorithms.

Wearables: From Fitness Trackers to Continuous Health Monitoring

Wearable technology has evolved significantly. While initially focused on fitness tracking, wearables are now capable of continuous, multi-parameter health monitoring. The Apple Watch, for instance, can now detect atrial fibrillation and even estimate blood oxygen levels. But this is just the beginning.

Future wearables will incorporate more advanced sensors, capable of monitoring biomarkers in sweat, tears, and even interstitial fluid. Companies like Profusa are developing tiny, implantable sensors that can continuously monitor glucose levels and other vital signs. This data, combined with AI-powered analytics, will enable proactive health management and early disease detection.

Did you understand? The global wearable medical device market is projected to reach $28.2 billion by 2027, according to a report by Grand View Research.

The Metaverse and Virtual Reality in Healthcare

The metaverse, often associated with gaming and social interaction, is finding surprising applications in healthcare. Virtual reality (VR) is being used for pain management, rehabilitation, and even surgical training. XRHealth, for example, offers VR-based therapeutic programs for a range of conditions, from chronic pain to stroke recovery.

The potential extends beyond therapy. VR and augmented reality (AR) can be used to enhance medical education, allowing students to practice complex procedures in a safe and realistic environment. The metaverse could facilitate remote patient consultations and support groups, improving access to care for underserved populations.

Telehealth 2.0: Beyond Video Calls

Telehealth experienced a surge in popularity during the pandemic, but the future of remote care goes far beyond simple video calls. We’re seeing the emergence of “hospital at home” programs, where patients receive acute care in the comfort of their own homes, monitored remotely by healthcare professionals and powered by connected devices.

These programs rely on a combination of telehealth technology, remote patient monitoring, and AI-powered analytics to provide a level of care comparable to that of a traditional hospital setting. Companies like Current Health are leading the way in this space, demonstrating the potential to reduce hospital readmissions and improve patient outcomes.

The Importance of Data Security and Interoperability

As healthcare becomes increasingly reliant on technology, data security and interoperability are paramount. Protecting patient data from cyberattacks is crucial, and ensuring that different healthcare systems can seamlessly exchange information is essential for coordinated care. Blockchain technology is being explored as a potential solution for enhancing data security and interoperability.

FAQ

  • Will AI replace doctors? No, AI is intended to augment the abilities of doctors, not replace them. It will handle repetitive tasks and provide insights to help doctors make more informed decisions.
  • How secure is my health data with these new technologies? Data security is a major concern. Healthcare providers and technology companies are investing heavily in cybersecurity measures to protect patient data.
  • Are digital therapeutics covered by insurance? Coverage varies. Some digital therapeutics are now covered by insurance, but it’s still an evolving landscape.
  • What is the metaverse’s role in healthcare? The metaverse offers opportunities for VR-based therapy, medical education, remote consultations, and patient support groups.

Pro Tip: Stay informed about the latest advancements in health tech by subscribing to industry newsletters and following thought leaders on social media.

Want to learn more about the intersection of technology and healthcare? Sign up for the STAT Health Tech newsletter for bi-weekly updates and in-depth analysis.

April 10, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

To lower drug prices, give PBMs a fiduciary duty to patients

by Chief Editor March 30, 2026
written by Chief Editor

The Shifting Landscape of Pharmacy Benefit Managers: Accountability and Transparency on the Horizon

For years, concerns have mounted regarding the role of pharmacy benefit managers (PBMs) in the prescription drug supply chain. Accusations of prioritizing profits over patient access and affordability have been widespread. Now, a confluence of Congressional action and Department of Labor (DOL) initiatives signals a potential turning point, aiming to align PBM incentives with those of employers and patients.

The PBM Model Under Scrutiny

PBMs act as intermediaries between health insurers, employers, and pharmaceutical companies. They negotiate drug prices, create formularies (lists of covered drugs), and process claims. However, the complexity of these arrangements has often lacked transparency, leading to questions about how rebates and discounts are utilized.

Research indicates that while PBMs negotiate, the benefits haven’t consistently translated to savings for payers or patients. A study highlighted that PBMs’ share of insulin expenditures nearly tripled between 2014 and 2018 without corresponding overall savings. Increased rebates have been linked to higher list prices, ultimately increasing out-of-pocket costs for individuals whose cost-sharing is tied to those list prices.

Recent Legislative and Regulatory Developments

The enactment of the Inflation Reduction Act of 2022 authorized the federal government to negotiate lower drug prices with manufacturers for some drugs covered by Medicare. More recently, the Consolidated Appropriations Act (CAA) mandated a broad framework for PBM transparency, making them the most transparent actor in the prescription drug supply chain.

Building on this momentum, in January 2026, the Department of Labor proposed a rule focused on improving transparency into PBM fee disclosure. This proposal aims to shed light on PBM practices and ensure fair pricing. However, the Pharmaceutical Care Management Association (PCMA) has urged the DOL to rescind the proposed rule, arguing it duplicates requirements already established in the CAA and imposes unnecessary burdens.

What’s Next for PBMs? Potential Future Trends

Several key trends are likely to shape the future of PBMs:

  • Increased Fiduciary Responsibility: A significant shift is the potential for PBMs to be held legally accountable as fiduciaries. This would require them to act in the best interests of their clients (employers and health plans) and beneficiaries (patients).
  • Enhanced Transparency: The CAA and the DOL’s proposed rule (despite challenges to its implementation) are driving a demand for greater transparency in PBM operations. Expect more detailed reporting on fees, rebates, and spread pricing (the difference between what a PBM pays a pharmacy and what it bills the health plan).
  • Rise of Pass-Through PBMs: A growing number of employers are opting for “pass-through” PBM arrangements, where all rebates and discounts are directly passed on to the plan sponsor, eliminating potential conflicts of interest.
  • Vertical Integration Challenges: The trend of PBMs acquiring or partnering with pharmacies and other healthcare providers will likely face increased scrutiny to ensure fair competition and prevent anti-competitive practices.

Impact on Patients and Employers

These changes have the potential to deliver significant benefits:

  • Lower Drug Costs: Increased transparency and negotiation power could lead to lower net drug costs for employers and patients.
  • Improved Access to Medications: More equitable formulary design and reduced administrative burdens could improve patient access to necessary medications.
  • Greater Plan Sponsor Control: Employers and health plans will have more insight into PBM operations and greater control over their pharmacy benefits.

FAQ

  • What is spread pricing? Spread pricing is the difference between what a PBM pays a pharmacy for a drug and what it bills the health plan.
  • What does it mean for PBMs to be fiduciaries? It means they are legally obligated to act in the best interests of their clients and beneficiaries.
  • Will these changes immediately lower my prescription drug costs? The impact will likely be gradual as new regulations are implemented and contracts are renegotiated.

Pro Tip: Employers should actively review their PBM contracts and consider requesting a full audit of PBM performance to ensure they are receiving the best possible value.

Did you realize? The Department of Labor’s proposed rule follows a similar approach to state-level PBM regulations already in place in several states.

Stay informed about the evolving landscape of pharmacy benefit management and advocate for policies that prioritize affordability and access to essential medications. Explore additional resources on the Department of Labor’s Employee Benefits Security Administration (EBSA) website for the latest updates and guidance.

March 30, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Insilico CEO Praises Eli Lilly as AI Leader Amid $2.75B Deal

by Chief Editor March 30, 2026
written by Chief Editor

AI-Powered Drug Discovery: Lilly and Insilico Medicine Forge a $2.75 Billion Partnership

The pharmaceutical landscape is undergoing a seismic shift, driven by the integration of artificial intelligence (AI) into drug discovery. A recent collaboration between Eli Lilly and Insilico Medicine, valued at up to $2.75 billion, exemplifies this trend. The deal, announced on March 29, 2026, highlights the growing confidence in AI’s ability to accelerate and improve the traditionally lengthy and expensive process of bringing modern drugs to market.

The Power of Pharma.AI

Insilico Medicine, a clinical-stage biotechnology company, is leveraging its proprietary Pharma.AI platforms to identify and develop novel therapeutics. This collaboration grants Eli Lilly an exclusive worldwide license to develop, manufacture, and commercialize a portfolio of preclinical candidates discovered using Insilico’s AI engine. Alex Zhavoronkov, founder and CEO of Insilico Medicine, emphasized the company’s focus on “deep learning for end-to-end drug discovery,” enabling the identification of multi-purpose targets driving multiple diseases simultaneously.

Zhavoronkov’s Praise for Lilly: A Strategic Alignment?

Zhavoronkov has publicly expressed admiration for Eli Lilly, even citing their drug tirzepatide as “the best drug ever invented by humans.” He has consistently praised Lilly for over a year, stating that they are leaders in AI within the pharmaceutical industry. While some might view these comments as influenced by the substantial financial agreement, Zhavoronkov maintains that his positive assessment is genuine, and that Lilly is the “absolutely best partner” for the licensed candidates.

Focus on Oral Therapeutics and GLP-1 Targets

The collaboration specifically focuses on the development of novel oral therapeutics. Insilico Medicine recently out-licensed a candidate targeting GLP-1 (glucagon-like peptide-1) to an undisclosed partner, suggesting a potential area of interest within the partnership. GLP-1 receptor agonists, like Lilly’s Mounjaro and Zepbound, are used in the treatment of type 2 diabetes and obesity, representing a significant market opportunity.

The Biobuck Bonanza: Deal Terms and Implications

The deal structure includes an upfront payment of $115 million to Insilico Medicine, with the potential for an additional $2.75 billion in milestone payments tied to regulatory and commercial success. This substantial investment underscores the perceived value of Insilico’s AI capabilities and the potential for significant returns for both companies. Zhavoronkov noted that this deal is crucial for Insilico, showcasing their ability to design novel molecules in a competitive market.

Future Trends in AI-Driven Drug Discovery

This partnership is indicative of several key trends shaping the future of pharmaceutical research:

  • Increased AI Adoption: More pharmaceutical companies will integrate AI and machine learning into their drug discovery pipelines.
  • Focus on Oral Therapeutics: Oral drugs are generally preferred by patients due to convenience and cost-effectiveness, driving demand for AI-driven discovery of oral formulations.
  • Generative AI’s Role: Generative AI, as utilized by Insilico, will become increasingly important in designing novel molecules with desired properties.
  • Strategic Partnerships: Collaboration between AI-focused biotech companies and established pharmaceutical giants will become more common.
  • Personalized Medicine: AI will facilitate the development of personalized therapies tailored to individual patient characteristics.

Pro Tip:

Keep an eye on companies investing heavily in AI infrastructure and talent. These are likely to be at the forefront of the next wave of pharmaceutical innovation.

FAQ

Q: What is Pharma.AI?
A: Pharma.AI is Insilico Medicine’s suite of AI platforms designed for end-to-end drug discovery, from target identification to preclinical candidate selection.

Q: What are GLP-1 receptor agonists?
A: GLP-1 receptor agonists are a class of drugs used to treat type 2 diabetes and obesity by mimicking the effects of the naturally occurring GLP-1 hormone.

Q: What are “biobucks”?
A: “Biobucks” is a common term in the pharmaceutical industry referring to milestone payments made to biotech companies based on the achievement of specific development, regulatory, and commercial goals.

Q: What is Insilico Medicine’s role in this partnership?
A: Insilico Medicine will leverage its AI engine to discover and develop novel therapeutic candidates, which Lilly will then develop, manufacture, and commercialize.

Want to learn more about the intersection of AI and biotechnology? Explore our other articles on drug discovery and personalized medicine.

March 30, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Novo Nordisk, FDA Approvals & Weekend Reads – Pharmalot Roundup

by Chief Editor March 29, 2026
written by Chief Editor

Novo Nordisk’s Strategic Shift: Candy Executive Joins Board as Obesity Market Heats Up

Novo Nordisk, a leading pharmaceutical company, is bolstering its consumer focus with a surprising appointment: Poul Weihrauch, CEO of Mars, the candy company, as a board observer. This move signals a strategic pivot as Novo Nordisk aims to strengthen its position in the competitive U.S. Obesity market.

The appointment follows a broader leadership shake-up within Novo Nordisk and its foundation last year, including changes to the CEO role and board structure. Lars Rebien Sorensen, now board chair, has emphasized the need for increased pharmaceutical and commercial expertise, particularly in navigating the challenges of the U.S. Market.

Novo Nordisk is actively working to enhance its consumer credentials, exemplified by the January launch of Wegovy in pill form through cash-pay channels, bypassing traditional insurance routes. This suggests a willingness to explore alternative distribution models to reach a wider audience.

What Does This Indicate for the Future of Obesity Treatment?

The inclusion of a consumer packaged goods executive on the board suggests a growing recognition of the importance of branding, marketing and direct-to-consumer strategies in the pharmaceutical industry. Expect to see more pharmaceutical companies adopting similar approaches, focusing on building consumer trust and awareness alongside clinical efficacy.

FDA Approves Gene Therapy for Rare Disease, Signals Flexibility in Manufacturing

The U.S. Food and Drug Administration has granted approval to Kresladi, a gene therapy developed by Rocket Pharma, for the treatment of severe leukocyte adhesion deficiency type 1 (LAD-1). This ultra-rare disease leaves children highly susceptible to life-threatening infections.

Kresladi initially faced rejection in 2024 due to manufacturing concerns. But, the FDA’s recent approval indicates a potential shift towards greater flexibility in manufacturing requirements for gene therapies, aiming to accelerate access to these potentially life-saving treatments.

Even as Kresladi is expected to carry a multi-million dollar price tag, its impact on Rocket Pharma’s bottom line may be limited due to the rarity of LAD-1, affecting approximately 1 in a million people, with around 25 recent cases identified annually.

The Value of FDA Priority Review Vouchers

Despite the limited market size, the approval of Kresladi earns Rocket Pharma a valuable FDA priority review voucher. This voucher can be used to expedite the approval process for another drug, reducing the typical review time from 10 months to just six. These vouchers are a significant asset, often traded or sold to other pharmaceutical companies.

Looking Ahead: Trends in Gene Therapy and Pharmaceutical Strategy

These developments highlight several key trends shaping the future of the pharmaceutical industry:

  • Increased Focus on Consumer Engagement: Pharmaceutical companies are increasingly recognizing the need to connect directly with consumers, building brand awareness and trust.
  • FDA Flexibility for Rare Disease Treatments: The FDA appears willing to adapt its manufacturing requirements to facilitate the approval of therapies for ultra-rare diseases.
  • The Growing Value of Priority Review Vouchers: These vouchers are becoming increasingly valuable as companies seek to accelerate the approval of their drugs.
  • Strategic Board Appointments: Companies are looking beyond traditional pharmaceutical expertise when building their leadership teams.

Did you know?

The FDA priority review voucher program was established to incentivize the development of drugs for rare diseases and unmet medical needs.

FAQ

What is LAD-1?
Leukocyte adhesion deficiency type 1 is a rare genetic disorder that impairs the ability of white blood cells to function properly, leading to severe and recurrent infections.

What is a priority review voucher?
A priority review voucher allows a pharmaceutical company to have its drug application reviewed by the FDA in a shorter timeframe.

Why did Novo Nordisk appoint a candy executive to its board?
Novo Nordisk aims to strengthen its consumer focus and marketing strategies as it competes in the growing obesity market.

Will gene therapies develop into more affordable?
While currently expensive, increased competition and manufacturing efficiencies may lead to lower prices for gene therapies in the future.

Pro Tip: Stay informed about pharmaceutical industry news and regulatory changes to understand the evolving landscape of drug development and approval.

Explore more articles on pharmaceutical innovation and regulatory affairs to deepen your understanding of these critical trends.

March 29, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Pharma & Biotech Moves: Averna Therapeutics Hires CSO Robert Mabry | STAT News

by Chief Editor March 29, 2026
written by Chief Editor

Averna Therapeutics Bolsters Leadership: What It Signals for the Future of Gene Therapy

Averna Therapeutics’ recent appointments of Robert Mabry as Chief Scientific Officer (CSO) and Richard Morris as Chief Financial Officer (CFO) aren’t just internal shifts; they represent a strategic move within the rapidly evolving landscape of genomic medicine. These hires, announced on March 26, 2026, signal a heightened focus on translating cutting-edge science into viable, scalable therapies.

The Rise of Gene Insertion Technology

Averna Therapeutics is focused on gene insertion technology, a critical area within gene therapy. Traditional viral-based gene therapies, while promising, face limitations in payload size and potential immune responses. Non-viral approaches, like Averna’s, aim to overcome these hurdles. The company’s approach utilizes RNA instructions that convert to stable DNA, delivered via lipid nanoparticles (LNPs). This method offers the potential for broader applicability and customizable treatments.

The appointment of Dr. Mabry, with his background at Hillstar Bio and Takeda Pharmaceuticals, is particularly noteworthy. His experience leading Hillstar Bio, focused on precision immunotherapy, suggests a potential convergence of gene editing and immune modulation strategies. This is a growing trend, as researchers explore ways to enhance the efficacy and specificity of gene therapies.

Why Now? The Growing Demand for Genomic Medicine Expertise

The biotech industry is experiencing a surge in demand for leaders with expertise in genomic medicine. Several factors are driving this trend. First, the success of early gene therapies has validated the approach, attracting significant investment. Second, advancements in technologies like CRISPR and RNA-based therapies are expanding the possibilities. Third, the increasing understanding of the genetic basis of disease is creating a larger pipeline of potential targets.

Richard Morris’s appointment as CFO underscores the financial complexities of developing and commercializing these advanced therapies. Building a financially sustainable genomic medicines company requires a leader with a proven track record in corporate finance and company building – precisely Morris’s expertise.

The Role of Site-Specific Retrotransposons

Averna’s specific approach centers on site-specific retrotransposons, naturally occurring genetic elements that insert DNA into “safe harbor” locations within the genome. This minimizes the risk of disrupting essential cellular functions, a major concern with earlier gene editing techniques. Leveraging these natural systems, combined with RNA and LNP delivery, represents a potentially transformative strategy.

Did you know? Retrotransposons have evolved over billions of years to efficiently and safely insert genetic material, offering a blueprint for engineered gene insertion systems.

Looking Ahead: Potential Trends in Genomic Medicine

Several key trends are likely to shape the future of genomic medicine:

  • Increased Focus on Non-Viral Delivery: Expect continued innovation in non-viral delivery systems, like LNPs, to improve safety and scalability.
  • Convergence of Gene Editing and Immunotherapy: Combining gene editing with immune modulation strategies to create more targeted and effective therapies.
  • Personalized Genomic Medicine: Tailoring gene therapies to individual patients based on their genetic profiles.
  • Expansion of Addressable Diseases: Moving beyond rare genetic disorders to tackle more common diseases with a genetic component.

FAQ

Q: What is gene insertion technology?
A: Gene insertion technology aims to introduce new or missing genetic instructions into cells to treat disease, offering a potential alternative to traditional gene editing approaches.

Q: What are lipid nanoparticles (LNPs)?
A: LNPs are tiny particles used to deliver genetic material, like RNA, into cells.

Q: What are retrotransposons?
A: Retrotransposons are naturally occurring genetic elements that can insert DNA into the genome, and Averna is leveraging them for safe and precise gene insertion.

Pro Tip: Keep an eye on companies like Averna Therapeutics, as they are at the forefront of developing innovative gene therapy technologies.

Want to learn more about the latest advancements in genomic medicine? Visit Averna Therapeutics’ website to explore their platform and pipeline.

March 29, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

White House Drafts Drug Pricing Legislation, Shares with Pharma Companies

by Chief Editor March 29, 2026
written by Chief Editor

Trump Administration Pushes for Legislative Drug Pricing Reform

Washington D.C. – The White House is actively working to translate its voluntary drug pricing agreements with pharmaceutical companies into formal legislation. Officials are currently sharing draft legislative text with over a dozen major pharmaceutical companies, signaling a continued commitment to lowering prescription drug costs.

Building on Voluntary Agreements

The proposed legislation closely mirrors the framework of the deals already struck with companies like Pfizer, AstraZeneca, Eli Lilly, and Novo Nordisk. These initial agreements focused on linking U.S. Drug prices to those paid in other developed nations – a “most favored nation” (MFN) policy. The new legislative text aims to codify this approach and expand its reach.

Cash Payments and Deductibles: A Key Component

A significant element of the draft legislation involves allowing payments made in cash for prescriptions to count towards a patient’s annual deductible. This provision could incentivize patients to seek lower cash prices, potentially increasing competition and driving down overall costs. Currently, many insurance plans do not credit cash payments towards deductibles.

Broader Healthcare Reform Efforts

The push for drug pricing legislation is part of a larger effort by the Trump administration to achieve comprehensive healthcare reform. With an election year underway, the President is prioritizing affordability initiatives, elevating the profile of these efforts. This suggests a strategic move to address a key voter concern.

Nine Additional Pharma Companies Join the Effort

In December 2025, President Trump announced agreements with nine additional biopharmaceutical companies: Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi. These companies have committed to lowering prices on drugs treating conditions like type two diabetes, rheumatoid arthritis, and certain cancers.

Tariff Relief as Incentive

A key incentive for pharmaceutical companies to participate in these agreements is a three-year grace period from potential pharmaceutical-specific tariffs. The administration has used the threat of tariffs as leverage to secure price concessions. Companies are also committing to invest at least $150 billion collectively in U.S. Manufacturing.

Strategic API Reserve Strengthened

Three of the companies involved in the drug pricing deals – Amgen, Bristol Myers Squibb, and Boehringer Ingelheim – are donating active pharmaceutical ingredients (APIs) for key products to the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR). This aims to reduce reliance on foreign nations and ensure a stable supply of essential medications within the United States.

Impact on Medicaid Programs

The agreements will provide access to MFN drug prices on products made by the nine companies to every State Medicaid program, potentially resulting in billions of dollars in savings for the program and its beneficiaries.

Future Trends and Implications

The move towards legislative action suggests a long-term strategy to reshape the pharmaceutical pricing landscape. Further developments could include:

Increased Transparency

Pressure for greater transparency in drug pricing is likely to continue. Legislative efforts may focus on requiring pharmaceutical companies to disclose more information about their pricing decisions and research and development costs.

Expansion of MFN Pricing

The MFN policy could be expanded to cover a wider range of drugs and potentially applied to other healthcare services.

Continued Use of Tariff Leverage

The administration may continue to use the threat of tariffs as a negotiating tactic to secure lower drug prices from companies that are reluctant to participate in voluntary agreements.

FAQ

Q: What is the “most favored nation” (MFN) pricing policy?
A: It aims to link U.S. Drug prices to the lowest prices paid in other developed nations.

Q: How will the cash payment provision affect patients?
A: It could allow patients who pay cash for prescriptions to apply those payments towards their annual deductibles.

Q: What is the role of tariffs in these agreements?
A: Pharmaceutical companies receive a three-year grace period from potential tariffs in exchange for agreeing to lower drug prices and invest in U.S. Manufacturing.

Q: Which companies have reached agreements with the Trump administration?
A: Agreements have been reached with AstraZeneca, Eli Lilly, Novo Nordisk, Pfizer, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi.

Did you know? Approximately 30% to 40% of drugs sold to Medicaid currently have prices higher than those paid in other nations.

Pro Tip: Patients should always compare prices at different pharmacies and explore available discount programs to find the lowest possible cost for their medications.

Stay informed about the latest developments in healthcare policy. Explore our other articles on drug pricing and healthcare reform to gain a deeper understanding of these complex issues.

March 29, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

FDA Outlines 2026 Food Safety & Labeling Priorities | STAT

by Chief Editor March 28, 2026
written by Chief Editor

FDA Shifts Focus to Food Safety: What’s on the Horizon for 2026

Washington D.C. – The Food and Drug Administration (FDA) is signaling a significant shift in priorities, with a heightened focus on food safety issues for 2026. Recent briefings to senators reveal a multi-pronged approach encompassing infant formula, food labeling, ultra-processed foods, inspections, and seafood safety.

Infant Formula Safety: A Top Priority

Following recent concerns and supply chain disruptions, the FDA is placing renewed emphasis on ensuring the safety of infant formula. The agency regulates the production of infant formulas to ensure they are safe and support healthy infant growth. Manufacturers are required to notify the FDA before marketing a new formula, and the FDA has the authority to remove products that don’t meet requirements from the market.

Pro Tip: Parents and caregivers can find up-to-date information and resources on infant formula safety directly on the FDA’s Infant Formula Homepage.

Decoding Ultra-Processed Foods

A key area of focus for the FDA in 2026 will be defining and understanding “ultra-processed foods.” This emerging category of food products, often high in sugar, fat, and salt, has come under scrutiny for its potential health impacts. The FDA’s efforts to define these foods could lead to new labeling requirements or regulations.

Modernizing Food Labels

Updating food labels is another priority for the agency. This could involve clearer presentation of nutritional information, allergen labeling, or the inclusion of information about ultra-processed ingredients. The goal is to empower consumers to make more informed food choices.

Boosting Food Processing Plant Inspections

The FDA plans to expand inspections of food processing plants. This increased oversight aims to identify and address potential safety hazards before they impact consumers. More frequent and thorough inspections are expected to be a cornerstone of the agency’s food safety strategy.

Strengthening Seafood Safety Programs

Seafood safety is too receiving increased attention. The FDA will be bolstering programs designed to prevent contamination and ensure the safe sourcing and handling of seafood products. This includes addressing concerns about mercury levels and other potential hazards.

A Shift in Political Winds

This increased focus on food policy comes as the administration’s health agenda appears to be shifting. Recent polls suggest that food reforms are more popular with the public than vaccine policies, influencing the administration’s messaging strategy.

Frequently Asked Questions

What does the FDA do regarding infant formula?

The FDA regulates the production of infant formulas to ensure they are safe and support healthy growth in infants. Manufacturers must notify the FDA before marketing a new formula.

Are all infant formulas FDA approved?

The FDA does not approve infant formulas, but manufacturers must notify the agency before marketing a new formula.

What are ultra-processed foods?

The FDA is working to define ultra-processed foods, which are often high in sugar, fat, and salt and have been linked to potential health concerns.

Stay informed about the latest developments in food safety and regulation by visiting the FDA website.

What are your biggest concerns about food safety? Share your thoughts in the comments below!

March 28, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

NIH Crackdown & China’s Rise: Biotech News Roundup

by Chief Editor March 27, 2026
written by Chief Editor

China’s Biotech Rise: A Global Reshaping of Drug Development

The biotech landscape is undergoing a significant shift, with China rapidly emerging as a dominant force. This ascent is not happening in isolation; it’s intertwined with challenges to global collaboration and a wave of consolidation within the industry.

NIH Restrictions and the Impact on Global Research

Recent crackdowns by the National Institutes of Health (NIH) on foreign subawards are creating friction in international research partnerships. These restrictions, intended to protect intellectual property, are inadvertently scrambling established collaborations and potentially slowing down the pace of scientific discovery. The impact is being felt across various research areas, forcing scientists to reassess long-standing partnerships.

The Allure of China: Talent and Investment

While the US faces increased scrutiny of international collaborations, China is actively attracting biotech talent and investment. The recent move of Wang Leyao, a human microbiome scientist, from a US government agency to China exemplifies this trend. This influx of expertise, coupled with substantial financial backing, is accelerating China’s biotech capabilities.

A Commercial Future for Gene Editing?

Despite setbacks in some areas, like Wave Life Sciences’ recent disappointing results in obesity trials, the long-term outlook for gene editing remains positive. Industry experts anticipate a wave of mergers and acquisitions (M&A) as companies seek to consolidate resources and accelerate the commercialization of gene editing technologies. This consolidation could lead to more efficient drug development and more effective treatments.

The Shifting Sands of Biotech Leadership

Concerns are growing among biotech leaders about the potential for the industry to become overly reliant on China. This isn’t simply about competition; it’s about the concentration of power and the potential implications for innovation and global health security. The current trajectory suggests a significant transfer of influence, prompting calls for a reevaluation of strategies to maintain a balanced and competitive landscape.

What Does This Mean for Drug Development?

China’s biotech boom is rewriting the rules of drug development. The country is no longer solely a manufacturing hub; it’s becoming a center for innovation, clinical trials, and commercialization. This shift is likely to lead to:

  • Faster Development Timelines: China’s streamlined regulatory processes and large patient populations can accelerate clinical trials.
  • Lower Costs: Research and development costs may be lower in China compared to the US and Europe.
  • Increased Competition: A more competitive landscape will drive innovation and potentially lower drug prices.

FAQ

Q: What are foreign subawards?
A: Foreign subawards are grants awarded by US institutions to researchers at foreign organizations to collaborate on research projects.

Q: Why is China attracting biotech talent?
A: China offers significant investment, state support, and opportunities for rapid career advancement in the biotech sector.

Q: What is the potential impact of M&A activity in biotech?
A: M&A can lead to greater efficiency, resource consolidation, and faster development of new therapies.

Did you know? The human microbiome is a rapidly growing area of research, and scientists like Wang Leyao are at the forefront of this field.

Pro Tip: Stay informed about the latest developments in biotech by subscribing to industry newsletters and following reputable news sources.

Explore more articles on STAT News to stay up-to-date on the latest biotech trends.

March 27, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

FDA Approves Gene Therapy for Rare LAD-1 Immune Deficiency | Kresladi

by Chief Editor March 27, 2026
written by Chief Editor

FDA Greenlights First Gene Therapy for LAD-I: A Latest Era for Rare Disease Treatment

In a landmark decision, the U.S. Food and Drug Administration (FDA) has approved Kresladi (marnetegragene autotemcel), a gene therapy developed by Rocket Pharmaceuticals, for the treatment of severe Leukocyte Adhesion Deficiency Type I (LAD-I). This approval marks the first FDA-approved gene therapy specifically targeting this ultra-rare genetic immune disorder, offering a potential lifeline to children facing life-threatening infections.

Understanding LAD-I and the Impact of Kresladi

Severe LAD-I is caused by mutations in the ITGB2 gene, hindering the ability of white blood cells to effectively fight infections. Without treatment, children with LAD-I often succumb to recurrent and fatal bacterial and fungal infections in early childhood. The standard treatment, allogeneic hematopoietic stem cell transplant, isn’t always feasible, particularly when a matched sibling donor isn’t available.

Kresladi utilizes a patient’s own blood stem cells, genetically modified to introduce functional copies of the ITGB2 gene. This one-time treatment aims to correct the underlying genetic defect, enabling the immune system to function properly. The FDA’s approval specifically covers pediatric patients without a suitable HLA-matched sibling donor.

A Rocky Road to Approval and the Future of Gene Therapy

The path to approval wasn’t without hurdles. Rocket Pharmaceuticals initially faced rejection from the FDA in 2024 due to manufacturing concerns. However, the company successfully addressed these issues and resubmitted its Biologics License Application (BLA), receiving acceptance in October 2025 with a PDUFA date of March 28, 2026 – ultimately resulting in approval on March 26, 2026.

While Kresladi represents a significant breakthrough, its financial impact may be limited due to the rarity of LAD-I, affecting approximately one in a million people, with an estimated 25 new cases annually. Despite the high cost expected for this one-time treatment, the little patient population suggests it won’t turn into a blockbuster drug.

The Broader Implications for Rare Disease Treatment

Kresladi’s approval signals a growing acceptance of gene therapies for rare diseases. The FDA demonstrated a willingness to exercise regulatory flexibility, considering small patient populations and all available evidence during the review process. This approach is crucial for accelerating the development and approval of treatments for conditions with limited research and patient numbers.

This approval builds on the momentum of other recent gene therapy approvals, demonstrating the potential of these innovative therapies to address previously untreatable conditions. It also highlights the importance of continued investment in research and development of gene therapies for a wider range of rare diseases.

What’s Next for Rocket Pharmaceuticals?

Rocket Pharmaceuticals is now focused on making Kresladi available to patients who require it most. The company is also eligible for a Rare Pediatric Disease Priority Review Voucher, which can be sold or used to expedite the review of another drug application.

FAQ

What is LAD-I?
LAD-I is a rare genetic immune deficiency caused by mutations in the ITGB2 gene, preventing white blood cells from effectively fighting infections.

How does Kresladi perform?
Kresladi uses a patient’s own blood stem cells, genetically modified to correct the ITGB2 gene defect.

Is Kresladi a cure for LAD-I?
Kresladi aims to provide a long-term correction of the genetic defect, potentially eliminating the need for ongoing treatment. However, long-term follow-up studies are needed to confirm its durability.

Who is eligible for Kresladi?
Kresladi is approved for pediatric patients with severe LAD-I who do not have a matched sibling donor for stem cell transplant.

What is the cost of Kresladi?
The cost of Kresladi has not been publicly disclosed, but gene therapies are generally extremely expensive.

Did you understand? The FDA’s acceptance of the BLA resubmission for Kresladi was announced on October 14, 2025.

Pro Tip: Stay informed about the latest advancements in gene therapy by following reputable sources like the FDA and organizations dedicated to rare disease research.

Want to learn more about groundbreaking medical advancements? Explore our other articles on innovative therapies and rare disease research.

March 27, 2026 0 comments
0 FacebookTwitterPinterestEmail
Newer Posts
Older Posts

Recent Posts

  • Empowering Women in Cinema: Abidjan’s Scratch Film Festival Promotes Female Talent in Cote d’Ivoire

    June 2, 2026
  • Argentina’s World Cup Group Stage Kit Schedule Revealed

    June 2, 2026
  • ASUS ROG Celebrates 20 Years of Innovation at Computex 2026

    June 2, 2026
  • Beatrix Oroszi Appointed New National Chief Medical Officer

    June 2, 2026
  • Sports Watch Deal: Save €250, Now €849

    June 2, 2026

Popular Posts

  • 1

    Maya Jama flaunts her taut midriff in a white crop top and denim jeans during holiday as she shares New York pub crawl story

    April 5, 2025
  • 2

    Saar-Unternehmen hoffen auf tiefgreifende Reformen

    March 26, 2025
  • 3

    Marta Daddato: vita e racconti tra YouTube e podcast

    April 7, 2025
  • 4

    Unlocking Success: Why the FPÖ Could Outperform Projections and Transform Austria’s Political Landscape

    April 26, 2025
  • 5

    Mecimapro Apologizes for DAY6 Concert Chaos: Understanding the Controversy

    May 6, 2025

Follow Me

Follow Me
  • Cookie Policy
  • CORRECTIONS POLICY
  • PRIVACY POLICY
  • TERMS OF SERVICE

Hosted by Byohosting – Most Recommended Web Hosting – for complains, abuse, advertising contact: o f f i c e @byohosting.com


Back To Top
Newsy Today
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World